Factor V Leiden (R506Q) and risk of venous thromboembolism: A case-control study based on the Spanish population

Clinical Genetics

Volumn 52, Issue 4, 1997, Pages 206-210

  García Gala, José M ^a   Alvarez, Victoria ^a   Pinto, Carmen R ^a   Soto, Inmaculada ^a   Urgellés, Manuel F ^a   Menéndez, María J ^a   Carracedo, Carmen ^b   López Larrea, Carlos ^a   Coto, Eliecer ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Factor V; Factor V Leiden; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ARGININE; BLOOD CLOTTING FACTOR 5; GLUTAMINE;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PEDIGREE ANALYSIS; POPULATION GENETICS; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 1842404736     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.1997.tb02548.x     Document Type: Article

References (19)

1. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994: 369: 64-67.
2. Beufé S, Borg J-Y, Vasse M, Charbonnier F, Moreau V, Monconduit M, Frebourg T. Cosegregation of thrombosis with the factor V Q506 in an extended family with resistance to activated protein C. Br J Haematol 1995: 89: 659-662.
3. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993: 90: 1004-1008.
4. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995: 85: 607-614.
5. Dahlbäck B. Resistance to activated protein C, the Arg to Gln mutation in the factor V gene and venous thrombosis. Thromb Haemost 1995b: 73: 739-742.
6. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and managment. Blood 1996: 87: 3531-3544.
7. Kiesewetter S, Mackek M Jr, Davis C, Curristin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsui LC, Mickle J, Amos J, Highsmith WE, Schuber A, Witt DR, Crystal RG, Cutting GR. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993: 5: 274-278.
8. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport S. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood 1995: 85: 1704-1711.
9. Liu XY, Nelson D, Grant C, Morthland V, Goodnight S, Press RD. Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Diagnostic Mol Pathol 1995: 4: 191-197.
10. Leroy-Matheron C, Levent M, Pignon JM, Mendoca C, Gouault-Heilmann M. The 1691 G→A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996: 75: 4-10.
11. Peral B, Ong ACM, San Millán JL, Gamble V, Ress L, Harris PC. A stable, nonsense mutation associated with a case of infantile onset polycistic kidney disease 1 (PKD1). Hum Mol Genet 1996: 5: 539-542.
12. Rabès JP, Trossaert M, Conard J, Samama M, Giraudet P, Boileau C. Single-point mutation at Arg-506 of factor V associated with APC resistance and venous thromboembolism: improved detection by PCR-mediated site-directed mutagenesis. Thromb Haemost 1995: 74: 1379-1380.
13. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995: 346: 1133-1134.
14. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995: 92: 2800-2802.
15. Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996: 75: 229-232.
16. Rosendaal FR, Koster T, Vandenbroucke JP, Reistma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995: 85: 1504-1508.
17. Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506 - Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997: 336: 399-403.
18. Vandenbroucke JP, Koster T, Briët E, Reistma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994: 344: 1453-1457.
19. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994: 94: 2521-2524.